title: Pushing the limits: defeating leukemia stem cells by depleting telomerase.
abstract: Leukemia stem cells (LSCs), featuring unlimited self-renewal capacity and chemoresistance, are critical cellular targets for new treatments to improve outcomes for acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Bruedigam et al. (2014) demonstrate that inhibition of telomerase is damaging to LSCs and may represent a promising therapeutic approach in AML.
authors.affiliation: Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. Electronic address: ykuo@coh.org.
authors.forename: Ya-Huei
authors.initials: YH
authors.lastname: Kuo
authors.affiliation: Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. Electronic address: rbhatia@coh.org.
authors.forename: Ravi
authors.initials: R
authors.lastname: Bhatia
mesh_terms: D000818:Animals; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D009536:Niacinamide / Q000031:analogs & derivatives*; D019098:Telomerase / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D007211:Indoles; D016159:Tumor Suppressor Protein p53; D009536:Niacinamide; D019098:Telomerase